» Articles » PMID: 35600880

Exploring the Therapeutic Potential of Phytochemicals in Alzheimer's Disease: Focus on Polyphenols and Monoterpenes

Overview
Journal Front Pharmacol
Date 2022 May 23
PMID 35600880
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a chronic, complex neurodegenerative disorder mainly characterized by the irreversible loss of memory and cognitive functions. Different hypotheses have been proposed thus far to explain the etiology of this devastating disorder, including those centered on the Amyloid-β (Aβ) peptide aggregation, Tau hyperphosphorylation, neuroinflammation and oxidative stress. Nonetheless, the therapeutic strategies conceived thus far to treat AD neurodegeneration have proven unsuccessful, probably due to the use of single-target drugs unable to arrest the progressive deterioration of brain functions. For this reason, the theoretical description of the AD etiology has recently switched from over-emphasizing a single deleterious process to considering AD neurodegeneration as the result of different pathogenic mechanisms and their interplay. Moreover, much relevance has recently been conferred to several comorbidities inducing insulin resistance and brain energy hypometabolism, including diabetes and obesity. As consequence, much interest is currently accorded in AD treatment to a multi-target approach interfering with different pathways at the same time, and to life-style interventions aimed at preventing the modifiable risk-factors strictly associated with aging. In this context, phytochemical compounds are emerging as an enormous source to draw on in the search for multi-target agents completing or assisting the traditional pharmacological medicine. Intriguingly, many plant-derived compounds have proven their efficacy in counteracting several pathogenic processes such as the Aβ aggregation, neuroinflammation, oxidative stress and insulin resistance. Many strategies have also been conceived to overcome the limitations of some promising phytochemicals related to their poor pharmacokinetic profiles, including nanotechnology and synthetic routes. Considering the emerging therapeutic potential of natural medicine, the aim of the present review is therefore to highlight the most promising phytochemical compounds belonging to two major classes, polyphenols and monoterpenes, and to report the main findings about their mechanisms of action relating to the AD pathogenesis.

Citing Articles

The role of GZMA as a target of cysteine and biomarker in Alzheimer's disease, pelvic organ prolapse, and tumor progression.

Li Y, Wang Z, Kong M, Yong Y, Yang X, Liu C Front Pharmacol. 2024; 15:1447605.

PMID: 39228516 PMC: 11368878. DOI: 10.3389/fphar.2024.1447605.


High-Altitude Medicinal Plants as Promising Source of Phytochemical Antioxidants to Combat Lifestyle-Associated Oxidative Stress-Induced Disorders.

Ashraf M, Khan S, Misri S, Gaira K, Rawat S, Rawat B Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204080 PMC: 11357401. DOI: 10.3390/ph17080975.


Prediction of Quercetin Analogs for Targeting Death-Associated Protein Kinase 1 (DAPK1) Against Alzheimer's Disease.

Sun Y, Zhao J, Lu Y, Ngo F, Shuai B, Zhang Z Curr Neuropharmacol. 2024; 22(14):2353-2367.

PMID: 38752632 PMC: 11451310. DOI: 10.2174/1570159X22666240515090434.


Anti-viral Effects of Methanolic Extract and Acyclovir on Behavioral and Biochemical Parameters in Streptozotocin-induced Alzheimer's Disease in Rats.

Kumar D, Singh G, Tarun , Dhanawat M, Gupta S, Morsy M Endocr Metab Immune Disord Drug Targets. 2024; 24(13):1558-1571.

PMID: 38685761 DOI: 10.2174/0118715303273145240110100341.


Protective Effect of Ferulic Acid on Acetylcholinesterase and Amyloid Beta Peptide Plaque Formation in Alzheimer's Disease: An In Vitro Study.

Mugundhan V, Arthanari A, Parthasarathy P Cureus. 2024; 16(2):e54103.

PMID: 38487137 PMC: 10938272. DOI: 10.7759/cureus.54103.


References
1.
Blahova J, Martiniakova M, Babikova M, Kovacova V, Mondockova V, Omelka R . Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus. Pharmaceuticals (Basel). 2021; 14(8). PMC: 8398612. DOI: 10.3390/ph14080806. View

2.
Zhang J, Feng X, Wu J, Xu H, Li G, Zhu D . Neuroprotective effects of resveratrol on damages of mouse cortical neurons induced by β-amyloid through activation of SIRT1/Akt1 pathway. Biofactors. 2013; 40(2):258-67. DOI: 10.1002/biof.1149. View

3.
Hirohata M, Ono K, Takasaki J, Takahashi R, Ikeda T, Morinaga A . Anti-amyloidogenic effects of soybean isoflavones in vitro: Fluorescence spectroscopy demonstrating direct binding to Aβ monomers, oligomers and fibrils. Biochim Biophys Acta. 2012; 1822(8):1316-24. DOI: 10.1016/j.bbadis.2012.05.006. View

4.
Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M . Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci. 2007; 27(50):13635-48. PMC: 6673606. DOI: 10.1523/JNEUROSCI.3949-07.2007. View

5.
Kurochkin I, Guarnera E, Berezovsky I . Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease. Trends Pharmacol Sci. 2017; 39(1):49-58. DOI: 10.1016/j.tips.2017.10.008. View